A recent meta-analysis has provided compelling evidence that cognitive behavioural therapy (CBT) significantly reduces the severity of body dysmorphic disorder (BDD) symptoms. Conducted by researchers from Northwest Minzu University, this study synthesises data from 11 randomised controlled trials (RCTs), encompassing 667 participants, to assess the efficacy of CBT in treating BDD, a chronic mental health condition characterised by obsessive preoccupation with perceived flaws in physical appearance.
BDD, which affects approximately 1.7% to 2.9% of the population, is associated with high levels of distress, impairment, and suicidality. Traditional treatment approaches for BDD often include pharmacotherapy, particularly serotonin reuptake inhibitors (SRIs), and psychological interventions like CBT. However, despite its widespread clinical use, the empirical support for CBT as the leading treatment for BDD has remained relatively limited until now.
The meta-analysis, which has been published in the Journal of Affective Disorders, reveals that CBT markedly reduces not only the severity of BDD symptoms but also associated conditions such as depression and anxiety. The BDD-YBOCS, which is a modified version of the Yale-Brown Obsessive-Compulsive Scale, showed a significant decrease in symptoms in people who received cognitive behavioural therapy (CBT). The SMD was -1.73, which means the effect size was quite large.
CBT was also found to be effective in improving patients’ quality of life and reducing dysfunctional beliefs related to their appearance. The meta-regression analysis further identified age and sample size as predictive factors of CBT’s effectiveness, suggesting that younger patients and those in larger studies tend to benefit more from the therapy.
The findings of this meta-analysis are particularly significant given the chronic nature of BDD and its association with high rates of suicidality. Despite the promising results, the study’s authors caution that, while CBT is effective, it should not yet be considered the definitive treatment for BDD due to the high heterogeneity observed across the studies analysed. The study found that heterogeneity was over 75% for most outcomes, which suggests that factors such as the mode of CBT delivery, patient characteristics, and study designs could influence the treatment’s efficacy.
The researchers also emphasise the importance of developing and testing digital and internet-based CBT (iCBT) interventions. Such approaches could enhance accessibility, particularly for individuals who face barriers to traditional therapy, such as cost, scheduling, and stigma. The study found that iCBT could be as effective as traditional face-to-face therapy, which opens up new avenues for making evidence-based treatments more widely available.
Despite the encouraging findings, the study highlights the need for more high-quality RCTs to solidify CBT’s position as a first-line treatment for BDD. The current evidence base, while growing, remains insufficient to conclusively establish CBT’s superiority over other treatments. The study also notes the necessity for long-term follow-up studies to assess the durability of CBT’s effects on BDD.
